MCID: SNS003
MIFTS: 53

Sensory Peripheral Neuropathy

Categories: Neuronal diseases

Aliases & Classifications for Sensory Peripheral Neuropathy

MalaCards integrated aliases for Sensory Peripheral Neuropathy:

Name: Sensory Peripheral Neuropathy 12 15
Sensory Neuropathy 12 74 29 54 6 15 71
Hereditary Sensory and Autonomic Neuropathies 71
Peripheral Sensory Neuropathy 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2491
ICD9CM 34 356.2
MeSH 43 D009477
NCIt 49 C3501
SNOMED-CT 67 11442006 95662005
UMLS 71 C0027889 C0151313 C0699739

Summaries for Sensory Peripheral Neuropathy

Disease Ontology : 12 A neuropathy that involves damage to nerves of the peripheral nervous system.

MalaCards based summary : Sensory Peripheral Neuropathy, also known as sensory neuropathy, is related to hereditary motor and sensory neuropathy, type iic and neuropathy, hereditary motor and sensory, russe type, and has symptoms including hyperesthesia, dysesthesia and sciatica. An important gene associated with Sensory Peripheral Neuropathy is MPZ (Myelin Protein Zero), and among its related pathways/superpathways are Guidance Cues and Growth Cone Motility and Neural Crest Differentiation. The drugs Methylcobalamin and Hydroxocobalamin have been mentioned in the context of this disorder. Affiliated tissues include breast, lung and skin, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Peripheral neuropathy, often shortened to neuropathy, is a general term describing disease affecting the... more...

Related Diseases for Sensory Peripheral Neuropathy

Diseases related to Sensory Peripheral Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 639)
# Related Disease Score Top Affiliating Genes
1 hereditary motor and sensory neuropathy, type iic 34.8 MPZ MFN2 GJB1 GDAP1
2 neuropathy, hereditary motor and sensory, russe type 34.3 NDRG1 GDAP1 EGR2
3 hereditary sensory and autonomic neuropathy type 1 34.2 SPTLC1 LITAF GDAP1
4 charcot-marie-tooth disease, axonal, type 2a1 34.1 MPZ MFN2 GDAP1
5 charcot-marie-tooth disease/hereditary motor and sensory neuropathy 33.9 SPTLC1 SLC12A6 PRX PMP22 MPZ MFN2
6 neuropathy, hereditary sensory and autonomic, type iia 33.9 SPTLC1 SLC12A6 NGF MFN2 LITAF GDAP1
7 charcot-marie-tooth disease, demyelinating, type 1b 33.9 PRX PMP22 MTMR2 MPZ MFN2 LITAF
8 neuropathy, hereditary sensory and autonomic, type ic 33.8 SPTLC1 LITAF
9 roussy-levy hereditary areflexic dystasia 33.7 PMP22 MPZ
10 neuropathy, hereditary sensory and autonomic, type v 33.7 SPTLC1 NGF
11 charcot-marie-tooth disease, axonal, type 2b2 33.6 MPZ MFN2 GDAP1
12 charcot-marie-tooth disease, demyelinating, type 1a 33.5 PRX PMP22 NTF3 MTMR2 MPZ MFN2
13 charcot-marie-tooth disease, type 4d 33.5 NDRG1 MTMR2 MPZ LITAF GJB1 GDAP1
14 charcot-marie-tooth disease, demyelinating, type 1c 33.5 PRX PMP22 MTMR2 MPZ LITAF GJB1
15 charcot-marie-tooth disease, demyelinating, type 1d 33.5 PRX PMP22 MTMR2 MPZ LITAF GJB1
16 charcot-marie-tooth disease, axonal, type 2b 33.3 SPTLC1 MTMR2 MPZ MFN2 LITAF GJB1
17 charcot-marie-tooth disease x-linked recessive 4 33.3 MPZ GJB1
18 charcot-marie-tooth disease, type 4b1 33.2 PRX MTMR2 MPZ LITAF GDAP1 FGD4
19 motor peripheral neuropathy 33.1 SLC12A6 PMP22 MAG LITAF GJB1 GDAP1
20 charcot-marie-tooth disease, axonal, type 2d 33.1 MPZ MFN2 GJB1 GDAP1
21 charcot-marie-tooth disease, type 4a 33.1 PRX MTMR2 MPZ MFN2 GJB1 GDAP1
22 charcot-marie-tooth disease, axonal, type 2b1 33.1 MFN2 GDAP1
23 charcot-marie-tooth disease, type 4b2 33.1 PRX MTMR2 MPZ LITAF GJB1 GDAP1
24 charcot-marie-tooth disease type 2a2a 33.1 MPZ MFN2 LITAF GJB1 GDAP1
25 neuropathy, hereditary, with liability to pressure palsies 33.0 PRX PMP22 NDRG1 MTMR2 MPZ MFN2
26 charcot-marie-tooth disease, x-linked recessive, 2 33.0 MPZ LITAF GJB1 EGR2
27 charcot-marie-tooth disease 33.0 SPTLC1 SLC12A6 PRX PMP22 NTF3 NGF
28 hereditary neuropathies 33.0 PRX PMP22 NDRG1 MTMR2 MPZ MFN2
29 charcot-marie-tooth disease intermediate type 32.9 MTMR2 MPZ MFN2 LITAF GJB1 GDAP1
30 charcot-marie-tooth disease and deafness 32.9 SPTLC1 PRX PMP22 NDRG1 MTMR2 MPZ
31 charcot-marie-tooth disease, axonal, type 2e 32.6 SPTLC1 SLC12A6 PRX PMP22 NGF NDRG1
32 neuropathy, congenital hypomyelinating, 1, autosomal recessive 32.6 SLC12A6 PRX PMP22 NTF3 NDRG1 MTMR2
33 charcot-marie-tooth disease, x-linked dominant, 1 32.1 SPTLC1 PRX PMP22 MTMR2 MPZ MFN2
34 charcot-marie-tooth disease, axonal, type 2n 32.1 MFN2 GDAP1
35 charcot-marie-tooth disease, axonal, type 2p 32.0 LITAF GDAP1
36 charcot-marie-tooth disease, recessive intermediate a 32.0 MFN2 GDAP1
37 charcot-marie-tooth disease, axonal, type 2f 31.9 SPTLC1 MTMR2 MPZ MFN2 GJB1 GDAP1
38 charcot-marie-tooth disease, type 4c 31.7 MTMR2 MPZ MFN2 LITAF GJB1 GDAP1
39 hypertrophic neuropathy of dejerine-sottas 31.7 SPTLC1 PRX PMP22 NDRG1 MTMR2 MPZ
40 charcot-marie-tooth disease, dominant intermediate e 31.6 MTMR2 MPZ GDAP1
41 charcot-marie-tooth disease, dominant intermediate c 31.6 SPTLC1 MPZ GDAP1
42 charcot-marie-tooth disease, axonal, type 2l 31.5 SPTLC1 MPZ MFN2 GDAP1
43 charcot-marie-tooth disease, dominant intermediate a 31.5 PRX MPZ GJB1 GDAP1
44 charcot-marie-tooth disease, axonal, type 2q 31.5 MPZ GJB1 EGR2
45 axonal neuropathy 31.5 PMP22 MFN2 GDAP1
46 charcot-marie-tooth disease, axonal, type 2r 31.5 SLC12A6 GDAP1
47 charcot-marie-tooth disease, demyelinating, type 1f 31.4 MTMR2 MPZ LITAF GJB1 FGD4
48 charcot-marie-tooth disease, type 4b3 31.4 MTMR2 GDAP1
49 charcot-marie-tooth disease, axonal, type 2j 31.4 MTMR2 MPZ MFN2 GDAP1 EGR2
50 charcot-marie-tooth disease, dominant intermediate b 31.4 MTMR2 MPZ LITAF GJB1 GDAP1

Graphical network of the top 20 diseases related to Sensory Peripheral Neuropathy:



Diseases related to Sensory Peripheral Neuropathy

Symptoms & Phenotypes for Sensory Peripheral Neuropathy

UMLS symptoms related to Sensory Peripheral Neuropathy:


hyperesthesia, dysesthesia, sciatica, neurologic symptoms

GenomeRNAi Phenotypes related to Sensory Peripheral Neuropathy according to GeneCards Suite gene sharing:

26 (show all 43)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.39 GJB1
2 Decreased viability GR00221-A-1 10.39 ELAVL4
3 Decreased viability GR00221-A-2 10.39 ELAVL4
4 Decreased viability GR00381-A-1 10.39 FGD4 MPZ PRX
5 Decreased viability GR00381-A-3 10.39 MPZ
6 Decreased viability GR00402-S-2 10.39 CCT4 EGR2 ELAVL3 ELAVL4 FGD4 FLVCR1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.23 FGD4
8 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.23 FGD4
9 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.23 SLC12A6
10 Increased shRNA abundance (Z-score > 2) GR00366-A-108 10.23 NTF3
11 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.23 FGD4 GJB1 NTF3 SLC12A6
12 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.23 NTF3
13 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.23 FGD4
14 Increased shRNA abundance (Z-score > 2) GR00366-A-140 10.23 FGD4
15 Increased shRNA abundance (Z-score > 2) GR00366-A-143 10.23 GJB1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.23 FGD4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.23 NTF3
18 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.23 GJB1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-173 10.23 SLC12A6
20 Increased shRNA abundance (Z-score > 2) GR00366-A-180 10.23 SLC12A6
21 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.23 GJB1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.23 SLC12A6
23 Increased shRNA abundance (Z-score > 2) GR00366-A-200 10.23 SLC12A6
24 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.23 NTF3
25 Increased shRNA abundance (Z-score > 2) GR00366-A-205 10.23 FGD4
26 Increased shRNA abundance (Z-score > 2) GR00366-A-208 10.23 GJB1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.23 SLC12A6
28 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.23 GJB1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-215 10.23 SLC12A6
30 Increased shRNA abundance (Z-score > 2) GR00366-A-26 10.23 NTF3
31 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.23 SLC12A6
32 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.23 SLC12A6
33 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.23 GJB1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-51 10.23 GJB1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-56 10.23 FGD4
36 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.23 NTF3
37 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.23 SLC12A6
38 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.23 SLC12A6
39 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.23 NTF3
40 Increased shRNA abundance (Z-score > 2) GR00366-A-92 10.23 FGD4
41 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.23 SLC12A6
42 Increased gamma-H2AX phosphorylation GR00053-A 9.81 CCT4 EGR2 ELAVL4 GJB1 MAG MPZ
43 no effect GR00402-S-1 9.62 CCT4 EGR2 ELAVL3 ELAVL4 FGD4 FLVCR1

MGI Mouse Phenotypes related to Sensory Peripheral Neuropathy:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.3 EGR2 ELAVL3 ELAVL4 FGD4 GDAP1 GJB1
2 growth/size/body region MP:0005378 10.13 EGR2 FGD4 FLVCR1 GJB1 MFN2 MPZ
3 homeostasis/metabolism MP:0005376 10.13 EGR2 ELAVL3 ELAVL4 FLVCR1 GDAP1 GJB1
4 mortality/aging MP:0010768 9.97 EGR2 ELAVL3 ELAVL4 FLVCR1 GJB1 MFN2
5 nervous system MP:0003631 9.91 EGR2 ELAVL3 ELAVL4 FGD4 GDAP1 GJB1
6 reproductive system MP:0005389 9.32 EGR2 ELAVL4 FLVCR1 GDAP1 MPZ MTMR2

Drugs & Therapeutics for Sensory Peripheral Neuropathy

Drugs for Sensory Peripheral Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 181)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
2
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
3
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
4
Mexiletine Approved, Investigational Phase 4 31828-71-4 4178
5
Nortriptyline Approved Phase 4 72-69-5 4543
6
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
7
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
8
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
9
Pyridoxal Phosphate Approved, Investigational, Nutraceutical Phase 4 54-47-7 1051
10
Cobalamin Experimental Phase 4 13408-78-1 6857388
11 Vitamin B Complex Phase 4
12 Vitamin B 12 Phase 4
13 Vitamin B12 Phase 4
14 Vitamin B 6 Phase 4
15 Adrenergic Agents Phase 4
16 Anesthetics, Local Phase 4
17 Anti-Arrhythmia Agents Phase 4
18 Sodium Channel Blockers Phase 4
19 Anesthetics Phase 4
20 Diuretics, Potassium Sparing Phase 4
21 Antidepressive Agents, Tricyclic Phase 4
22 Excitatory Amino Acids Phase 4
23 Excitatory Amino Acid Antagonists Phase 4
24 Antimanic Agents Phase 4
25
Pyridoxal Experimental, Nutraceutical Phase 4 66-72-8 1050
26
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
27
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
28
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
29
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
30
Acetylcholine Approved, Investigational Phase 3 51-84-3 187
31
Baclofen Approved Phase 3 1134-47-0 2284
32
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
33
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
34
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
35
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
36
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
37
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
38
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
39
Olaparib Approved Phase 3 763113-22-0 23725625
40
Norepinephrine Approved Phase 2, Phase 3 51-41-2 439260
41
Dopamine Approved Phase 2, Phase 3 51-61-6, 62-31-7 681
42
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
43
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 6857599 43805
44
Perphenazine Approved Phase 2, Phase 3 58-39-9 4748
45
Amitriptyline Approved Phase 2, Phase 3 50-48-6 2160
46
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
47 Tocotrienol Investigational Phase 3 6829-55-6
48
Cediranib Investigational Phase 3 288383-20-0 9933475
49
Maleic acid Experimental, Investigational Phase 3 110-17-8, 110-16-7 444972
50
Xaliproden Investigational Phase 3 135354-02-8, 428863-50-7 128919

Interventional clinical trials:

(show top 50) (show all 104)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double Blind, Placebo Controlled Prospective Study to Evaluate the Effectiveness of Monochromatic Infrared Photo Energy to Improve Diabetic Sensory Neuropathy Completed NCT00120341 Phase 4
2 A Prospective, Open-label Trial of Lidoderm® (Lidocaine Patch 5%)in Painful Diabetic and Idiopathic Neuropathy. Completed NCT00903851 Phase 4 Lidoderm
3 A 24 Week, Double-blind, Placebo-controlled, Multisite Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
4 Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS) Completed NCT02260388 Phase 4 Nortriptyline;Duloxetine;Pregabalin;Mexiletine
5 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
6 Randomized Phase 3 Study of Xelox(Capecitabine Plus Oxaliplatin) Followed by Maintenance Capecitabine or Observation in Patients With Advanced Gastric Adenocarcinoma Unknown status NCT02289547 Phase 3 Capecitabine
7 Phase III Study of Acetyl-L-Carnitine (ALC) Hydrochloride Enteric-coated Tablets in Treatment of Peripheral Sensory Neuropathy in Anti-cancer Chemotherapeutics Induce Completed NCT01526564 Phase 3 Acetylcarnitine;Placebo
8 A Multicenter Randomized Dble-Blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin and 5-FU/LV Combination in First-Line Treatment of Patients With Metastatic Colorectal Carcinoma(MCRC) Completed NCT00272051 Phase 3 SR57746A
9 A Multicenter, Randomized Double-blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Preventing the Neurotoxicity of Oxaliplatin in First-line Treatment of Patients With Metastatic Colorectal Cancer Treated With Oxaliplatin / 5-FU/LV Completed NCT00305188 Phase 3 Xaliproden (SR57746A);Placebo;Oxaliplatin;5-Fluorouracil;Leucovorin
10 A Multicentre, Randomized, Open-label, Phase III Study Comparing the Efficacy of Oral Glutamine and Calcium-magnesium With Calcium-magnesium Alone in the Prevention of Oxaliplatin-induced Neurotoxicity in Patients With Colorectal Cancer Treated With Oxaliplatin in Adjuvant or 1st Line Metastatic Settings. Completed NCT01087658 Phase 3 Glutamine;Calcium and Magnesium
11 A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients. Completed NCT00659269 Phase 3 Chemotherapy
12 The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study Completed NCT00363129 Phase 3
13 PHASE III, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Pregabalin in Prevention and Reduction of Oxaliplatin-induced Painful Neuropathy Completed NCT01450163 Phase 3 Pregabalin, Oxaliplatin;Placebo , Oxaliplatin
14 The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study Completed NCT00516503 Phase 3 baclofen/amitriptyline/ketamine gel
15 A Randomized, Phase III Clinical Trial to Compare Sentinel Node Resection to Conventional Axillary Dissection in Clinically Node-Negative Breast Cancer Patients Completed NCT00003830 Phase 3
16 Efficacy and Safety of Xeomin for the Treatment of Notalgia Paresthetica Completed NCT01098019 Phase 3 Xeomin;Placebo / Xeomin
17 Phase 2 Study for Infrared Thermometry Used by Diabetic Patients at Home Completed NCT00289497 Phase 2, Phase 3
18 ESSAI DE PHASE III RANDOMISE EVALUANT LE FOLFOX AVEC OU SANS DOCETAXEL (TFOX) EN 1ère LIGNE DE CHIMIOTHERAPIE DES ADENOCARCINOMES OESO-GASTRIQUES LOCALEMENT AVANCES OU METASTATIQUES Recruiting NCT03006432 Phase 3 Oxaliplatin;5Fluorouracil bolus;5Fluorouracil continu;Docetaxel;Folinic Acid
19 A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) Recruiting NCT02502266 Phase 2, Phase 3 Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride
20 A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
21 Double-blind Placebo Controlled Trial of the Treatment of Chronic Laryngitis With Amitriptyline Enrolling by invitation NCT02552225 Phase 2, Phase 3 Amitriptyline
22 Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study Not yet recruiting NCT04137107 Phase 2, Phase 3 Oxaliplatin;Duloxetine Hydrochloride;Duloxetine
23 A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer Suspended NCT02037529 Phase 3 Eribulin Mesylate;Paclitaxel
24 A Multi-center, Randomized, Double Blind, Placebo Controlled Phase III Study to Assess the Efficacy of Xaliproden in Patients With Oxaliplatin-induced Peripheral Sensory Neuropathy (PSN) Following Adjuvant Chemotherapy for Colon Cancer Terminated NCT00603577 Phase 3 Placebo;Xaliproden
25 Double-blind Placebo Controlled Trial of the Treatment of Chronic Laryngitis With Amitryptiline Terminated NCT02434523 Phase 2, Phase 3 Amitriptyline
26 Phase 3 Study: The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients Terminated NCT00529633 Phase 3 Thalidomide
27 A Randomized, Double-Blinded, Placebo Controlled Phase III Trial Using Acetyl-L-Carnitine(ALC)(NSC# 747431) for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Patients With Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer Withdrawn NCT01492920 Phase 3
28 Prospective Comparison the Pharmacokinetics of Subcutaneous Versus Intravenous Administration of Bortezomib in Newly Diagnosed Patients of Multiple Myeloma in China. Unknown status NCT01812096 Phase 1, Phase 2
29 A Study of Prophylactic Oral Steroids for Fatigue and Malaise Due to Regorafenib Treatment for Unresectable Metastatic Colorectal Cancer: a Randomized, Placebo-controlled, Double-blind Phase 2 Clinical Study (KSCC1402/HGCSG1402) Unknown status NCT02288078 Phase 2 Dexamethasone;Regorafenib;Placebo;Proton pump inhibitor
30 The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study: A Phase II Study of Chemo - Hormonal Therapy and Radiation in High Risk Prostate Cancer Unknown status NCT00452556 Phase 2 Docetaxel;Leuprolide Acetate (Eligard®)
31 A Randomized Phase II Trial of Capecitabine Plus Cisplatin (XP) Versus Capecitabine Plus Paclitaxel (XT) as a First-line Treatment for Advanced or Recurrent Esophageal Squamous Cell Carcinoma Unknown status NCT00816634 Phase 2 Capecitabine plus cisplatin(XP) versus capecitabine plus paclitaxel(XT)
32 Effect of C-Peptide on Diabetic Peripheral Neuropathy, a 6 Months Randomized Double-Blind, Placebo Controlled, Dose-Finding, Multicenter Study, With Parallel Groups Completed NCT00278980 Phase 2 C-peptide
33 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of L-Serine in Subjects With Hereditary Sensory Neuropathy Type 1 Completed NCT01733407 Phase 1, Phase 2 L-serine;placebo
34 A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy Completed NCT00000842 Phase 2 Nerve Growth Factor, Recombinant Human
35 Phase II Trial of Metronomic Eribulin (Halaven) in Pretreated Metastatic Breast Cancer (MBC) Completed NCT01908101 Phase 2 Eribulin Mesylate
36 The Efficacy of MC5-A ("Scrambler") Therapy in the Management of Chemotherapy-Induced Peripheral Neuropathy: A Phase II Pilot Trial Completed NCT00952848 Phase 2
37 VELCADE (Bortezomib) and Thalidomide in Newly Diagnosed Patients With Multiple Myeloma Completed NCT00287872 Phase 2 bortezomib;thalidomide
38 Phase 2 Study of Ascorbic Acid Treatment in Charcot-Marie-Tooth Type 1A Completed NCT00271635 Phase 2 Placebo;ascorbic acid
39 Topiramate as a Disease Modifying Therapy for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN) Recruiting NCT02878798 Phase 2 topiramate
40 Nicotinamide Riboside (NR) in Paclitaxel-induced Peripheral Neuropathy Recruiting NCT03642990 Phase 2 Nicotinamide Riboside
41 Symptom Management Efficacy Study to Reduce Distal Neuropathic Pain Recruiting NCT03855111 Phase 2
42 Efficacy and Safety of Modified Nab-Paclitaxel Plus Gemcitabine Chemotherapy for Metastatic Pancreatic Cancer: A Single-arm Phase II Clinical Trial Recruiting NCT03502343 Phase 2 Modified Gemcitabine plus nab-Paclitaxel Combination Chemotherapy
43 Phase II Evaluation of the Effect of 2 Versus 6 Hour Oxaliplatin Infusions on Neuropathy and Pharmacokinetics in Patients With Gastrointestinal Cancers Recruiting NCT03800693 Phase 2 Fluorouracil;Leucovorin;Oxaliplatin
44 A Phase IIa Proof of Concept, Randomized, Double-blind, Placebo-controlled Study of the Effects of L-serine on Early Stage Alzheimer's Disease Patients Recruiting NCT03062449 Phase 2 L-Serine
45 Randomized Phase II Study Comparing 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI Followed by Two Months of Gemcitabine+Nab-paclitaxel, in Metastatic Pancreatic Cancer Recruiting NCT03693677 Phase 2 Irinotecan Liposomal Injection;5-FU/LV;Nab-Paclitaxel;Gemcitabine
46 Phase II Trial of Infusional 5 FLUOROURACIL, LEUCOVORIN, OXALIPLATIN AND IRINOTECAN (FOLFIRINOX) in First Line Treatment of Advanced Biliary Tract Cancers Recruiting NCT03291899 Phase 2
47 Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy Not yet recruiting NCT03571334 Phase 2 IncobotulinumtoxinA (Xeomin®, Merz) (INA);Normal saline
48 Phase II Trial of Modified FOLFIRINOX in Patients With Metastatic Biliary Tract Cancer After Failure of Gemcitabine/Cisplatin Chemotherapy Not yet recruiting NCT03778593 Phase 2 5-Fluorouracil;Leucovorin;Irinotecan;Oxaliplatin
49 Phase II Study to Assess Prevention of Oxaliplatin-induced Neurotoxicity Through the Vitamin D Pathway Terminated NCT01499940 Phase 2 Vitamin D3
50 A Phase II, Randomized, Double Blind, Cross-over, Placebo-controlled Study on Norepinephrine Replenishment Therapy Using L-DOPS in Congenital Insensitivity to Pain With Anhidrosis Patients Withdrawn NCT02624310 Phase 2 Droxidopa (L-DOPS);Placebo

Search NIH Clinical Center for Sensory Peripheral Neuropathy

Genetic Tests for Sensory Peripheral Neuropathy

Genetic tests related to Sensory Peripheral Neuropathy:

# Genetic test Affiliating Genes
1 Sensory Neuropathy 29

Anatomical Context for Sensory Peripheral Neuropathy

MalaCards organs/tissues related to Sensory Peripheral Neuropathy:

40
Breast, Lung, Skin, Spinal Cord, Brain, Colon, Testes

Publications for Sensory Peripheral Neuropathy

Articles related to Sensory Peripheral Neuropathy:

(show top 50) (show all 4067)
# Title Authors PMID Year
1
Atypical, perhaps under-recognized? An unusual phenotype of Friedreich ataxia. 54 61
20162437 2010
2
Six new gap junction beta 1 gene mutations and their phenotypic expression in Czech patients with Charcot-Marie-Tooth disease. 54 61
20039784 2010
3
Genotype-phenotype correlations in Charcot-Marie-Tooth disease type 2 caused by mitofusin 2 mutations. 54 61
20008656 2009
4
Genes for hereditary sensory and autonomic neuropathies: a genotype-phenotype correlation. 54 61
19651702 2009
5
Hereditary motor and sensory neuropathy caused by a novel mutation in LITAF. 54 61
19541485 2009
6
[Hereditary peripheral neuropathies]. 54 61
19327944 2009
7
Andermann syndrome can be a phenocopy of hereditary motor and sensory neuropathy--report of a discordant sibship with a compound heterozygous mutation of the KCC3 gene. 54 61
20020398 2009
8
Retinal ganglion cell neurodegeneration in mitochondrial inherited disorders. 54 61
19268652 2009
9
[Polyneuropathy associated with monoclonal gammapathy: treatment perspectives]. 54 61
20120390 2009
10
Mutated mitofusin 2 presents with intrafamilial variability and brain mitochondrial dysfunction. 54 61
18946002 2008
11
Histopathological findings in hereditary motor and sensory neuropathy of axonal type with onset in early childhood associated with mitofusin 2 mutations. 54 61
18957892 2008
12
Hereditary motor and sensory neuropathy Lom type in a Serbian family. 54 61
19364063 2008
13
[Spectrum and frequency of mutations in the connexin 32 gene (GJB1) in hereditary and sensory neuropathy type 1X patients from Bashkortostan]. 54 61
19062535 2008
14
Aldose reductase, still a compelling target for diabetic neuropathy. 54 61
18220710 2008
15
K-Cl cotransport in red blood cells from patients with KCC3 isoform mutants. 54 61
17215889 2006
16
Early onset severe and late-onset mild Charcot-Marie-Tooth disease with mitofusin 2 (MFN2) mutations. 54 61
16835246 2006
17
Myelin protein zero mutation His39Pro: hereditary motor and sensory neuropathy with variable onset, hearing loss, restless legs and multiple sclerosis. 54 61
16844954 2006
18
Mutation in the epsilon subunit of the cytosolic chaperonin-containing t-complex peptide-1 (Cct5) gene causes autosomal recessive mutilating sensory neuropathy with spastic paraplegia. 54 61
16399879 2006
19
Clinical, pathological and genetic characterization of hereditary sensory and autonomic neuropathy type 1 (HSAN I). 54 61
16364956 2006
20
Impairment of Trk-neurotrophin receptor by the serum of a patient with subacute sensory neuropathy. 54 61
16216947 2005
21
Ganglioside-induced differentiation associated protein 1 is a regulator of the mitochondrial network: new implications for Charcot-Marie-Tooth disease. 54 61
16172208 2005
22
Analyses of the differentiation potential of satellite cells from myoD-/-, mdx, and PMP22 C22 mice. 54 61
15762989 2005
23
Effects of polyol pathway hyperactivity on protein kinase C activity, nociceptive peptide expression, and neuronal structure in dorsal root ganglia in diabetic mice. 54 61
15561956 2004
24
Clinical and electrophysiological studies of a family with probable X-linked dominant Charcot-Marie-Tooth neuropathy and ptosis. 54 61
15508871 2004
25
Genetic evaluation of inherited motor/sensory neuropathy. 54 61
16106622 2004
26
Clinical, electrophysiological and morphological findings of Charcot-Marie-Tooth neuropathy with vocal cord palsy and mutations in the GDAP1 gene. 54 61
12821518 2003
27
Mutation screening of the N-myc downstream-regulated gene 1 (NDRG1) in patients with Charcot-Marie-Tooth Disease. 54 61
12872253 2003
28
Regeneration of primary sensory neurons. 54 61
12595748 2003
29
Regulation of myotubularin-related (MTMR)2 phosphatidylinositol phosphatase by MTMR5, a catalytically inactive phosphatase. 54 61
12668758 2003
30
A new quantitative PCR multiplex assay for rapid analysis of chromosome 17p11.2-12 duplications and deletions leading to HMSN/HNPP. 54 61
12634865 2003
31
Clinical, electrophysiological and molecular genetic characteristics of 93 patients with X-linked Charcot-Marie-Tooth disease. 54 61
11571214 2001
32
Molecular basis of hereditary neuropathies. 54 61
11345007 2001
33
Phe 84 deletion of the PMP22 gene associated with hereditary motor and sensory neuropathy HMSN III with multiple cranial neuropathy: clinical, neurophysiological and magnetic resonance imaging findings. 54 61
11355152 2001
34
[Molecular genetics of hereditary neuropathies]. 54 61
11299480 2001
35
Steroid responsive polyneuropathy in a family with a novel myelin protein zero mutation. 54 61
11080236 2000
36
Inherited neuropathies: from gene to disease. 54 61
10219749 1999
37
Inherited peripheral neuropathy. 54 61
10716658 1999
38
Biological actions of nerve growth factor in the peripheral nervous system. 54 61
10023124 1999
39
PMP-22 gene duplications and deletions identified in archival, paraffin-embedded sural nerve biopsy specimens: correlation to structural changes. 54 61
9678509 1998
40
The first de novo mutation of the connexin 32 gene associated with X linked Charcot-Marie-Tooth disease. 54 61
9541114 1998
41
Expression of HuD (a paraneoplastic encephalomyelitis antigen) mRNA in lung cancer. 54 61
9288629 1997
42
Charcot-Marie-Tooth disease and related peripheral neuropathies. 54 61
10975746 1997
43
Two divergent types of nerve pathology in patients with different P0 mutations in Charcot-Marie-Tooth disease. 54 61
8797476 1996
44
Localization of a gene responsible for autosomal recessive demyelinating neuropathy with focally folded myelin sheaths to chromosome 11q23 by homozygosity mapping and haplotype sharing. 54 61
8817346 1996
45
Neurotrophic factors in the therapy of peripheral neuropathy. 54 61
8599726 1995
46
[A case of hereditary motor and sensory neuropathy type I with a new type of peripheral myelin protein (PMP)-22 mutation]. 54 61
8777804 1995
47
Structure and function of peripheral nerve myelin proteins. 54 61
7568893 1995
48
Molecular analysis of the HuD gene encoding a paraneoplastic encephalomyelitis antigen in human lung cancer cell lines. 54 61
8069866 1994
49
Neurotrophic growth factors and neurodegenerative diseases: therapeutic potential of the neurotrophins and ciliary neurotrophic factor. 54 61
7838303 1994
50
Molecular genetics of Charcot-Marie-Tooth disease and related neuropathies. 54 61
7849745 1994

Variations for Sensory Peripheral Neuropathy

ClinVar genetic disease variations for Sensory Peripheral Neuropathy:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 GDAP1 NM_018972.4(GDAP1):c.715C>T (p.Leu239Phe)SNV Pathogenic 4200 rs104894080 8:75276240-75276240 8:74364005-74364005
2 MPZ NM_000530.8(MPZ):c.293G>A (p.Arg98His)SNV Pathogenic/Likely pathogenic 14176 rs121913589 1:161276653-161276653 1:161306863-161306863
3 SPTLC3 NM_018327.4(SPTLC3):c.448T>C (p.Trp150Arg)SNV Likely pathogenic 243088 rs755919784 20:13053048-13053048 20:13072400-13072400
4 GJB1 NM_000166.6(GJB1):c.502T>G (p.Cys168Gly)SNV Likely pathogenic 373934 rs1057518780 X:70444059-70444059 X:71224209-71224209
5 MED25 NM_030973.3(MED25):c.1778_1779del (p.Gln593fs)deletion Uncertain significance 409952 rs763039409 19:50339015-50339016 19:49835758-49835759
6 AP1B1 NM_001127.3(AP1B1):c.637G>A (p.Glu213Lys)SNV Uncertain significance 598986 rs1569159579 22:29752494-29752494 22:29356505-29356505
7 SLC12A1 NM_001184832.2(SLC12A1):c.2255C>T (p.Ala752Val)SNV Uncertain significance 316268 rs137893258 15:48559858-48559858 15:48267661-48267661
8 POMT1 NM_001077365.2(POMT1):c.1793G>A (p.Arg598Gln)SNV Uncertain significance 373970 rs202140413 9:134396827-134396827 9:131521440-131521440

Expression for Sensory Peripheral Neuropathy

Search GEO for disease gene expression data for Sensory Peripheral Neuropathy.

Pathways for Sensory Peripheral Neuropathy

Pathways related to Sensory Peripheral Neuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.4 NGF MAG GDAP1
2 11.14 PMP22 MPZ GJB1
3
Show member pathways
10.62 NTF3 NGF MAG

GO Terms for Sensory Peripheral Neuropathy

Cellular components related to Sensory Peripheral Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 compact myelin GO:0043218 8.62 PMP22 MAG

Biological processes related to Sensory Peripheral Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrial fusion GO:0008053 9.4 MFN2 GDAP1
2 nerve development GO:0021675 9.37 NTF3 NGF
3 cell-cell adhesion via plasma-membrane adhesion molecules GO:0098742 9.32 MPZ MAG
4 nerve growth factor signaling pathway GO:0038180 9.26 NTF3 NGF
5 myelin assembly GO:0032288 9.16 PMP22 MTMR2
6 myelination GO:0042552 9.13 PMP22 MPZ EGR2
7 peripheral nervous system development GO:0007422 8.92 PMP22 NTF3 NGF EGR2

Sources for Sensory Peripheral Neuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....